Form 8-K - Current report:
SEC Accession No. 0001520138-21-000423
Filing Date
2021-08-11
Accepted
2021-08-11 13:23:10
Documents
18
Period of Report
2021-08-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT bivi-20210811_8k.htm   iXBRL 8-K 42806
2 EXHIBIT 1.1 bivi-20210811_8kex1z1.htm EX-1.1 234582
3 EXHIBIT 5.1 bivi-20210811_8kex5z1.htm EX-5.1 16645
4 EXHIBIT 99.1 bivi-20210811_8kex99z1.htm EX-99.1 9788
5 EXHIBIT 99.2 bivi-20210811_8kex99z2.htm EX-99.2 10290
6 GRAPHIC image_002.jpg GRAPHIC 2829
7 GRAPHIC image_004.jpg GRAPHIC 16869
  Complete submission text file 0001520138-21-000423.txt   592288

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE bivi-20210808.xsd EX-101.SCH 3045
9 XBRL LABEL FILE bivi-20210808_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE bivi-20210808_pre.xml EX-101.PRE 22372
11 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20210811_8k_htm.xml XML 3574
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

EIN.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39015 | Film No.: 211162834
SIC: 2834 Pharmaceutical Preparations